TY - JOUR
T1 - Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk
T2 - Multicenter Randomized Trial CROSS-J-RCC
AU - Tomita, Yoshihiko
AU - Naito, Sei
AU - Sassa, Naoto
AU - Takahashi, Atsushi
AU - Kondo, Tsunenori
AU - Koie, Takuya
AU - Obara, Wataru
AU - Kobayashi, Yasuyuki
AU - Teishima, Jun
AU - Takahashi, Masayuki
AU - Matsuyama, Hideyasu
AU - Ueda, Takeshi
AU - Yamaguchi, Kenya
AU - Kishida, Takeshi
AU - Shiroki, Ryoichi
AU - Saika, Takashi
AU - Shinohara, Nobuo
AU - Oya, Mototsugu
AU - Kanayama, Hiro omi
N1 - Funding Information:
Y.T. has received grants and lecture and advisory fees from Novartis , Japan; Ono , and Astellas , grants and lecture fees from Astellas and Pfizer , Japan lecture fees from Bristol-Myers Squibb , Japan and grants from Takeda, Japan . T. Kondo has received lecture fees from Intuitive Surgical, Novartis, Ono, and Pfizer. W.O. has received grants form Nipuro and Takeda and lecture fees from Astellas, Bristol-Myers Squibb, Ono, and Pfizer. J.T. has received lecture fees from Pfizer. M.T. has received lecture fees from Pfizer. H.M. has received grants and lecture fees from Janssen , grants from Kyowa-Hakko-Kirin , Japan; Merck biopharma , Japan; Sharp & Dohme , Takeda Terumo , and Toyo Steel . R.S. has received lecture fees from Intuitive Surgical and Novartis and a grant from Astellas . T.S. has received grants and lecture fees from Astellas and Takeda and lecture fees from Novartis. N. Shinohara has received grants and lecture fees from Astellas and Ono , lecture fees from Bayer, and lecture fees from Bayer, GlaxoSmithKline, Pfizer, and Takeda. M.O. has received grants and lecture fees from Pfizer and lecture fees from Bayer, Bristol-Myers Squibb, Novartis, and Ono. H.K. has received grant and lecture fees from Pfizer and grants from Astellas , Ono , Sanofi , Japan; Taiho , and Takeda . The remaining authors declare that they have no competing interests.
Funding Information:
The present study was supported in part by the Japanese Urological Research Network and Pfizer . The authors would like to thank Enago ( www.enago.jp ) for the English language review.
PY - 2020/8
Y1 - 2020/8
N2 - The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08).
AB - The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08).
UR - http://www.scopus.com/inward/record.url?scp=85085351126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085351126&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2020.01.001
DO - 10.1016/j.clgc.2020.01.001
M3 - Article
C2 - 32466961
AN - SCOPUS:85085351126
VL - 18
SP - e374-e385
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
SN - 1558-7673
IS - 4
ER -